A hybrid congress experience ensuring that the global diabetes community can get connected and benefit from the most recent developments in diabetes research, treatment, technologies and care.
Mogrify is transforming the lives of patients through the development of a novel class of in vivo reprogramming therapies, initially addressing indications in ophthalmology, otology and metabolic and other areas of degenerative disease. Using its proprietary suite of platform technologies to systematically identify the key transcriptomic and epigenetic switches required to drive direct cellular reprogramming.
Connect with our team virtually at the EASD Annual Meeting 2023.